TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03339479

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dielectric property test
Description: Test the dielectric property of resected lung nodules/mass through a touching probe after the lung tissue with nodules/mass has been resected and cut open, which usually takes only 1-5 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: frozen pathological examination
Description: And after the dielectric property test, the lung tissue will be sent for frozen pathological examination.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: final pathological examination
Description: All of the lung nodules/mass will be diagnosed by final pathological examination and recognized as the final diagnosis after surgery.
Study: NCT01974167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eldecalcitol
Description: Eldecalcitol 0.75 microgram once daily orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfacalcidol
Description: Alfacalcidol 1 microgram once daily orally
Study: NCT02926248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine is an anti-fibrotic and anti-inflammatory drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02159131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estadiol
Description: EE is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: LNG is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744
Description: GSK1265744 is available as 30 mg tablet to be taken along with 240 mL water
Study: NCT03878732

Intervention type: DIAGNOSTIC_TEST
Intervention: Bindex measurement
Description: One time bone density measurement with ultrasound device

Intervention type: DIAGNOSTIC_TEST
Intervention: Bindex measurement
Description: One time bone density measurement with ultrasound device
Study: NCT01314040

Intervention type: OTHER
Group type: OTHER
Intervention: Run in diet
Description: Fully controlled dietary period during 9 days. Participants will receive approximately 15 en% of protein. The amount of protein intake from dairy, meat, and grain will be equal to each other

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High meat protein diet
Description: Fully controlled diet during 7 days. Participants will consume 18 en% protein, mainly from meat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dairy protein diet
Description: Fully controlled dietary intervention during 7 days. Participants will consume 20 en% protein. Mainly from dairy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High grain protein diet
Description: Fully controlled dietary intervention for 7 days. Participants will consume 20 en% of protein. Mainly from grain
Study: NCT01704313

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interrupted
Description: Interrupted suturing technique used aroudn the heel of the vascular anastomosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous
Description: Continuous suturing technique used for the anastomosis
Study: NCT03243669

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Virtual chromoendoscopy
Description: Virtual chromoendoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Standard colonoscopy
Study: NCT03327766

Intervention type: DIAGNOSTIC_TEST
Intervention: 4-Measurment of serum 25(OH)D3 using Vidas by ELFA meathod.
Description: A specialized test of the 25(OH)D serum level was conducted and the blood samples were collected in the months of November to April. The winter months were chosen intentionally in order to limit the impact of the sun light upon 25(OH)D serum level.The test VIDAS® 25 OH Vitamin D Total was used-enzyme immunoassay with highly fluorescent measurement ELFA. According to the reference values of this method the 25(OH)D \< 20 ng/ml serum levels are considered as deficiency and the serum levels between 20 - 30ng/ml are defined as insufficiency. It's sufficient if the level of 25(OH)D is 30 to 100 ng/ml.

Intervention type: DIAGNOSTIC_TEST
Intervention: 4-Measurment of serum 25(OH)D3 using Vidas by ELFA meathod.
Description: A specialized test of the 25(OH)D serum level was conducted and the blood samples were collected in the months of November to April. The winter months were chosen intentionally in order to limit the impact of the sun light upon 25(OH)D serum level.The test VIDAS® 25 OH Vitamin D Total was used-enzyme immunoassay with highly fluorescent measurement ELFA. According to the reference values of this method the 25(OH)D \< 20 ng/ml serum levels are considered as deficiency and the serum levels between 20 - 30ng/ml are defined as insufficiency. It's sufficient if the level of 25(OH)D is 30 to 100 ng/ml.
Study: NCT03344679

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine 0.25%
Description: Bupivacaine 0.25% for PECS block

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine 0.25%
Description: Bupivacaine 0.25% for PECS block

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine 0.25%
Description: Bupivacaine 0.25% for PECS block

Intervention type: DRUG
Group type: OTHER
Intervention: Adenosine 12mg
Description: Adenosine 12 mg for PECS block

Intervention type: DRUG
Group type: OTHER
Intervention: Magnesium Sulphate 500 mg
Description: Magnesium sulphate 500 mg for PECS block
Study: NCT03228056

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: pain intensity measured in VAS scale
Description: Pain intensity in 0-100 mm VAS scale is measured every 4 hours on standard ruler beginning from the end of the surgery.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: pain intensity measured in VAS scale
Description: Pain intensity in 0-100 mm VAS scale is measured every 4 hours on standard ruler beginning from the end of the surgery.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pain intensity measured in VAS scale
Description: Pain intensity in 0-100 mm VAS scale is measured every 4 hours on standard ruler beginning from the end of the surgery.
Study: NCT03838926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichostatin A
Description: Intravenous Infusion
Study: NCT00550485

Intervention type: DRUG
Group type: OTHER
Intervention: escitalopram
Description: escitalopram 4 mg

Intervention type: DRUG
Group type: OTHER
Intervention: escitalopram
Description: escitalopram 4 mg
Study: NCT00388310

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Culture
Description: Culture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Culture
Description: Culture

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Culture
Description: Culture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Culture
Description: Culture
Study: NCT03907280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162 (T1)
Description: oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162 (T1)
Description: oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162 (T1)
Description: oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162 (T2)
Description: Solution for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162 (T2)
Description: Solution for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162 (T2)
Description: Solution for inhalation
Study: NCT03243669

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Standard colonoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Standard colonoscopy
Study: NCT04073602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.0 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
Study: NCT04031144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Description: At the end of CPB procedure, free water is partly removed by ultrafiltration to increase relative mass of red blood cell and plasma components.
Study: NCT02455648

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESD/EMR plus Cell Sheet
Description: Patients receive ESD/EMR plus CellSheet:~Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) that are inserted 2 weeks later on the occasion of the ESD or EMR

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: ESD/EMR
Description: only ESD/EMR: Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) but NOT used for insertion in the patient during/after ESD/EMR two weeks later
Study: NCT03595579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05
Description: AXS-05 taken twice daily for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion taken twice daily for 6 weeks.
Study: NCT03705208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Youth First Curriculum
Description: A 25 session emotional resilience and health curriculum designed for 7th and 8th grade students.
Study: NCT03099993

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of maximal forces of elbow pronosupination and flexion-extension
Description: Maximal forces of elbow pronosupination and flexion-extension will be measured with a portable dynamometer.

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of maximal forces of elbow pronosupination and flexion-extension
Description: Maximal forces of elbow pronosupination and flexion-extension will be measured with a portable dynamometer.

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of maximal forces of elbow pronosupination and flexion-extension
Description: Maximal forces of elbow pronosupination and flexion-extension will be measured with a portable dynamometer.
Study: NCT04604002

Intervention type: DEVICE
Intervention: OCT Angiography
Description: OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.

Intervention type: DEVICE
Intervention: OCT Angiography
Description: OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.

Intervention type: DEVICE
Intervention: Color Fundus Photography
Description: Non-contact white light photography

Intervention type: DEVICE
Intervention: Color Fundus Photography
Description: Non-contact white light photography

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: A non-contact test that uses light waves to take cross-sectional pictures of the retina

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: A non-contact test that uses light waves to take cross-sectional pictures of the retina
Study: NCT03103243

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Based Group Sessions
Description: In-person group intervention sessions conducted with a combination of meditation, group exercise (yoga), group discussions, deep breathing and other mindfulness based practices.
Study: NCT00811343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QFTB-G and T-SPOT.TB tests
Description: QFTB-G and T-SPOT.TB test before TST
Study: NCT01881139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Study: NCT01409148

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 124I-labeled monoclonal antibody Mu 11-1F4
Description: Single infusion of radiolabeled antibody: 2mCi (1 mg)
Study: NCT00981890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib is a tablet that is taken by mouth every day. Patients will be treated with Sunitinib alone for 7 days. On the seventh day of taking the drug they will be given SRS. Sunitinib will continue for seven days per week after SRS, and depending on how far along the study is when patients join, they may continue taking the drug for up to 13 weeks after SRS.
Study: NCT00817180

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Expiratory Pressure (PEP)
Description: Physiotherapy technique for airway clearance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System
Description: Physiotherapy technique for airway clearance.
Study: NCT04428879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Episcleral Plaque
Description: Sustained Release Episcleral Topotecan Plaques (Chemoplaques) are glued to bare, dry sclera of the eye under conjunctiva and Tenon's capsule. A rolling six dose interpatient escalation schema will be employed. Chemoplaques with 0.6 mg and 0.9 mg of topotecan HCl formulation are available. Patients will receive 1 or 2 Chemoplaques per eye, to deliver 5 escalating doses: 0.6, 0.9, 1.2 \[2x0.6\], 1.5 \[0.6+0.9\] or 1.8 \[2x0.9\] mg. The prescribed dose will escalate or de-escalate by 0.3 mg at each level, and no patient will receive more than 1.8 mg of topotecan hydrochloride due to the physical limitations if the devices available. The planned removal is 42 days ± 7, unless dose limiting toxicity is observed, in which case the plaque is removed as soon as possible. The observation period for the purposes of dose-escalation will be 63 days (i.e. 21 days following Chemoplaque removal on day 42).
Study: NCT00924287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin
Description: 720,000 IU/kg every 8 hours for a maximum of 15 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg/day x 2 days intravenously (IV) in 250 ml 5% dextrose in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 3 mg/kg/hour intravenously diluted in a suitable diluent over 23 hours after each cyclophosphamide dose.
Study: NCT00113880

Intervention type: BIOLOGICAL
Intervention: FluMist
Description: Nasal Sprayer dose of FluMist with annual follow up

Intervention type: BIOLOGICAL
Intervention: FluMist
Description: Nasal Sprayer dose of FluMist with annual follow up
Study: NCT03676426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web platform for advance care planning/advance directive
Description: Ourcarewishes (OCW) is a web-based platform to document advance care planning based at Penn. OCW contains more detailed content on preferences and values than a standard advance directive and allows electronic sharing with loved ones and transmission to the Penn EHR.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard advance directive
Description: Patients receive a paper copy of an advance directive used by social workers at Penn Medicine and are encouraged to complete on their own.
Study: NCT02145221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Study: NCT02297568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calciferol
Description: Comparison 25OHD levels between calciferol and placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00997087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil
Description: Sublingual daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flumazenil
Description: Sublingual daily
Study: NCT01785303

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I
Description: Cognitive Behavior Therapy for Insomnia (CBT-I) consists of 4 weekly sessions delivered individually. The focus of these sessions is on modifying behaviors and cognitions related to sleep and insomnia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I
Description: Cognitive Behavior Therapy for Insomnia (CBT-I) consists of 4 weekly sessions delivered individually. The focus of these sessions is on modifying behaviors and cognitions related to sleep and insomnia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP is an FDA-approved medical device used to treat obstructive sleep apnea. This device consists of a mask, hose, and machine that blows continuous air which maintains a consistent pressure of airflow preventing the upper airway from collapsing during sleep.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP is an FDA-approved medical device used to treat obstructive sleep apnea. This device consists of a mask, hose, and machine that blows continuous air which maintains a consistent pressure of airflow preventing the upper airway from collapsing during sleep.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CPAP
Description: CPAP is an FDA-approved medical device used to treat obstructive sleep apnea. This device consists of a mask, hose, and machine that blows continuous air which maintains a consistent pressure of airflow preventing the upper airway from collapsing during sleep.
Study: NCT01273233

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Enterovirus Type 71 Vaccine
Description: A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Enterovirus Type 71 Vaccine
Description: A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.
Study: NCT00240487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: Subjects will receive inhaled Nitric Oxide at a dose of 10 parts per million (ppm) for a 4 hour study period. Blood gases will be collected once an hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: Subjects will receive inhaled Nitric Oxide at a dose of 10 parts per million (ppm) for a 4 hour study period. Blood gases will be collected once an hour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Subjects will receive no intervention (i.e., no nitric oxide treatment) for a 4 hour study period. Blood gases will be collected once an hour. During this time, all subjects will receive standard clinical care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Subjects will receive no intervention (i.e., no nitric oxide treatment) for a 4 hour study period. Blood gases will be collected once an hour. During this time, all subjects will receive standard clinical care.
Study: NCT03105674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-drug local anesthetics (Combination)
Description: 1. Ropivacaine 0.5% - 30 ml~2. Ketorolac 30mg/ml - 1 ml~3. Kenalog 10 mg/ml - 5 ml~4. Lidocaine 1% with Epinephrine 1:100,000 - 20ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard local anesthetics (Combination)
Description: Marcaine and Lidocaine
Study: NCT00291148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Study: NCT04529668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D supplementation
Description: vitamin D supplementation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usual therapy for nasal polyposis
Description: steroids ( systemic and local )
Study: NCT01760239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS)
Description: The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR. The CDS tool includes six key features: (i) prompts regarding the need for height data to classify the BP by percentile (ii) prompts to repeat any BP that is ≥90% or ≥120/80 mm Hg (iii) classification of BPs by percentile, including classification of those in pre-HT, stage 1 HT and stage 2 HT range (iv) review of previous HT diagnoses and BPs in order to classify elevated BPs as incident (first or second elevated BP) or persistent (third or greater elevated BP) (v) tailored CDS based on HT category and previous diagnoses (vi) graphical representation of current and historical BP data by age and BP percentile.